\n \n \n
\n
\n\n \n \n \n \n \n \n Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study.\n \n \n \n \n\n\n \n El-Refai, S. M., Black, E. P., Adams, V. R., Talbert, J. C., & Brown, D.\n\n\n \n\n\n\n
Thrombosis Research, 158: 49–58. October 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{ElRefai2017,\n doi = {10.1016/j.thromres.2017.08.001},\n url = {https://doi.org/10.1016/j.thromres.2017.08.001},\n year = {2017},\n month = oct,\n publisher = {Elsevier {BV}},\n volume = {158},\n pages = {49--58},\n author = {Sherif M. El-Refai and Esther P. Black and Val R. Adams and Jeffery C. Talbert and D. Brown},\n title = {Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study},\n journal = {Thrombosis Research}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort.\n \n \n \n \n\n\n \n Brown, J. D., Raissi, D., Han, Q., Adams, V. R., & Talbert, J. C.\n\n\n \n\n\n\n
Journal of the American Heart Association, 6(9). September 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{Brown2017,\n doi = {10.1161/jaha.117.006708},\n url = {https://doi.org/10.1161/jaha.117.006708},\n year = {2017},\n month = sep,\n publisher = {Ovid Technologies (Wolters Kluwer Health)},\n volume = {6},\n number = {9},\n author = {Joshua D. Brown and Driss Raissi and Qiong Han and Val R. Adams and Jeffery C. Talbert},\n title = {Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large {US} Cohort},\n journal = {Journal of the American Heart Association}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates.\n \n \n \n \n\n\n \n El-Refai, S. M., Brown, J. D., Arnold, S. M., Black, E. P., Leggas, M., & Talbert, J. C.\n\n\n \n\n\n\n
JCO Clinical Cancer Informatics, (1): 1–12. November 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{ElRefai2017,\n doi = {10.1200/cci.17.00010},\n url = {https://doi.org/10.1200/cci.17.00010},\n year = {2017},\n month = nov,\n publisher = {American Society of Clinical Oncology ({ASCO})},\n number = {1},\n pages = {1--12},\n author = {Sherif M. El-Refai and Joshua D. Brown and Susanne M. Arnold and Esther P. Black and Markos Leggas and Jeffery C. Talbert},\n title = {Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates},\n journal = {{JCO} Clinical Cancer Informatics}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer.\n \n \n \n \n\n\n \n El-Refai, S. M, Brown, J. D, Black, E. P, & Talbert, J. C\n\n\n \n\n\n\n
Cancer Informatics, 16: 117693511771252. January 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{ElRefai2017,\n doi = {10.1177/1176935117712520},\n url = {https://doi.org/10.1177/1176935117712520},\n year = {2017},\n month = jan,\n publisher = {{SAGE} Publications},\n volume = {16},\n pages = {117693511771252},\n author = {Sherif M El-Refai and Joshua D Brown and Esther P Black and Jeffery C Talbert},\n title = {Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer},\n journal = {Cancer Informatics}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Predictors of Chronic Opioid Use in Newly Diagnosed Crohn's Disease.\n \n \n \n \n\n\n \n Pauly, N. J., Michailidis, L., Kindred, M. G., Flomenhoft, D., Lofwall, M. R., Walsh, S. L., Talbert, J. C., & Barrett, T. A.\n\n\n \n\n\n\n
Inflammatory Bowel Diseases, 23(6): 1004–1010. June 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{Pauly2017,\n doi = {10.1097/mib.0000000000001087},\n url = {https://doi.org/10.1097/mib.0000000000001087},\n year = {2017},\n month = jun,\n publisher = {Oxford University Press ({OUP})},\n volume = {23},\n number = {6},\n pages = {1004--1010},\n author = {Nathan J. Pauly and Lamprinos Michailidis and Michael G. Kindred and Deborah Flomenhoft and Michelle R. Lofwall and Sharon L. Walsh and Jeffery C. Talbert and Terrence A. Barrett},\n title = {Predictors of Chronic Opioid Use in Newly Diagnosed Crohn's Disease},\n journal = {Inflammatory Bowel Diseases}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Predictors of Chronic Opioid Use in Newly Diagnosed Crohn's Disease.\n \n \n \n \n\n\n \n Pauly, N. J., Michailidis, L., Kindred, M. G., Flomenhoft, D., Lofwall, M. R., Walsh, S. L., Talbert, J. C., & Barrett, T. A.\n\n\n \n\n\n\n
Inflammatory Bowel Diseases, 23(6): 1004–1010. June 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{Pauly2017,\n doi = {10.1097/mib.0000000000001087},\n url = {https://doi.org/10.1097/mib.0000000000001087},\n year = {2017},\n month = jun,\n publisher = {Oxford University Press ({OUP})},\n volume = {23},\n number = {6},\n pages = {1004--1010},\n author = {Nathan J. Pauly and Lamprinos Michailidis and Michael G. Kindred and Deborah Flomenhoft and Michelle R. Lofwall and Sharon L. Walsh and Jeffery C. Talbert and Terrence A. Barrett},\n title = {Predictors of Chronic Opioid Use in Newly Diagnosed Crohn's Disease},\n journal = {Inflammatory Bowel Diseases}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study.\n \n \n \n \n\n\n \n El-Refai, S. M., Black, E. P., Adams, V. R., Talbert, J. C., & Brown, J. D.\n\n\n \n\n\n\n
Thrombosis Research, 158: 49–58. October 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{ElRefai2017,\n doi = {10.1016/j.thromres.2017.08.001},\n url = {https://doi.org/10.1016/j.thromres.2017.08.001},\n year = {2017},\n month = oct,\n publisher = {Elsevier {BV}},\n volume = {158},\n pages = {49--58},\n author = {Sherif M. El-Refai and Esther P. Black and Val R. Adams and Jeffery C. Talbert and Joshua D. Brown},\n title = {Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study},\n journal = {Thrombosis Research}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.\n \n \n \n \n\n\n \n Brown, J. D., Shewale, A. R., & Talbert, J. C.\n\n\n \n\n\n\n
Journal of Managed Care & Specialty Pharmacy, 23(9): 958–967. September 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{Brown2017,\n doi = {10.18553/jmcp.2017.23.9.958},\n url = {https://doi.org/10.18553/jmcp.2017.23.9.958},\n year = {2017},\n month = sep,\n publisher = {Academy of Managed Care Pharmacy},\n volume = {23},\n number = {9},\n pages = {958--967},\n author = {Joshua D. Brown and Anand R. Shewale and Jeffery C. Talbert},\n title = {Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data},\n journal = {Journal of Managed Care {\\&} Specialty Pharmacy}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates.\n \n \n \n \n\n\n \n El-Refai, S. M., Brown, J. D., Arnold, S. M., Black, E. P., Leggas, M., & Talbert, J. C.\n\n\n \n\n\n\n
JCO Clinical Cancer Informatics, (1): 1–12. November 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{ElRefai2017,\n doi = {10.1200/cci.17.00010},\n url = {https://doi.org/10.1200/cci.17.00010},\n year = {2017},\n month = nov,\n publisher = {American Society of Clinical Oncology ({ASCO})},\n number = {1},\n pages = {1--12},\n author = {Sherif M. El-Refai and Joshua D. Brown and Susanne M. Arnold and Esther P. Black and Markos Leggas and Jeffery C. Talbert},\n title = {Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates},\n journal = {{JCO} Clinical Cancer Informatics}\n}\n\n
\n
\n\n\n\n
\n\n\n
\n
\n\n \n \n \n \n \n \n Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer.\n \n \n \n \n\n\n \n El-Refai, S. M, Brown, J. D, Black, E. P, & Talbert, J. C\n\n\n \n\n\n\n
Cancer Informatics, 16: 117693511771252. January 2017.\n
\n\n
\n\n
\n\n
\n\n \n \n
Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n
\n
@article{ElRefai2017,\n doi = {10.1177/1176935117712520},\n url = {https://doi.org/10.1177/1176935117712520},\n year = {2017},\n month = jan,\n publisher = {{SAGE} Publications},\n volume = {16},\n pages = {117693511771252},\n author = {Sherif M El-Refai and Joshua D Brown and Esther P Black and Jeffery C Talbert},\n title = {Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer},\n journal = {Cancer Informatics}\n}\n
\n
\n\n\n\n
\n\n\n\n\n\n